These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 9598119)
1. Dihydroorotate dehydrogenase. Profile of a novel target for antiproliferative and immunosuppressive drugs. Löffler M; Grein K; Knecht W; Klein A; Bergjohann U Adv Exp Med Biol; 1998; 431():507-13. PubMed ID: 9598119 [No Abstract] [Full Text] [Related]
2. Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects? Ullrich A; Knecht W; Fries M; Löffler M Eur J Biochem; 2001 Mar; 268(6):1861-8. PubMed ID: 11248707 [TBL] [Abstract][Full Text] [Related]
3. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Davis JP; Cain GA; Pitts WJ; Magolda RL; Copeland RA Biochemistry; 1996 Jan; 35(4):1270-3. PubMed ID: 8573583 [TBL] [Abstract][Full Text] [Related]
4. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Knecht W; Löffler M Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339 [TBL] [Abstract][Full Text] [Related]
5. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Knecht W; Henseling J; Löffler M Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902 [TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships (SAR) of some tetracyclic heterocycles related to the immunosuppressive agent Brequinar Sodium. Pitts WJ; Jetter JW; Pinto DJ; Orwat MJ; Batt DG; Sherk SR; Petraitis JJ; Jacobson IC; Copeland RA; Dowling RL; Jaffee BD; Gardner TL; Jones EA; Magolda RL Bioorg Med Chem Lett; 1998 Feb; 8(3):307-12. PubMed ID: 9871675 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents. Vyas VK; Variya B; Ghate MD Eur J Med Chem; 2014 Jul; 82():385-93. PubMed ID: 24929289 [TBL] [Abstract][Full Text] [Related]
9. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia. Sykes DB Expert Opin Ther Targets; 2018 Nov; 22(11):893-898. PubMed ID: 30318938 [No Abstract] [Full Text] [Related]
10. Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide. Williamson RA; Yea CM; Robson PA; Curnock AP; Gadher S; Hambleton AB; Woodward K; Bruneau JM; Hambleton P; Spinella-Jaegle S; Morand P; Courtin O; Sautés C; Westwood R; Hercend T; Kuo EA; Ruuth E Transplant Proc; 1996 Dec; 28(6):3088-91. PubMed ID: 8962196 [No Abstract] [Full Text] [Related]
11. In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine. Thomson TA; Spinella-Jaegle S; Francesconi E; Meakin C; Millet S; Flao KL; Hidden H; Ruuth E Scand J Immunol; 2002 Jul; 56(1):35-42. PubMed ID: 12100469 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium. Chen SF; Perrella FW; Behrens DL; Papp LM Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622 [TBL] [Abstract][Full Text] [Related]
13. Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide. Schorlemmer HU; Milbert U; Zeitter D; Haun G; Wunschel M; Bartlett RR Inflamm Res; 1999 Dec; 48 Suppl 2():S115-6. PubMed ID: 10667841 [No Abstract] [Full Text] [Related]
14. Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program. Cleaveland ES; Monks A; Vaigro-Wolff A; Zaharevitz DW; Paull K; Ardalan K; Cooney DA; Ford H Biochem Pharmacol; 1995 Mar; 49(7):947-54. PubMed ID: 7741767 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel substituted benzamide derivatives bearing a 1,2,3-triazole moiety as potent human dihydroorotate dehydrogenase inhibitors. Lu K; Cai L; Zhang X; Wu G; Xu C; Zhao Y; Gong P Bioorg Chem; 2018 Feb; 76():528-537. PubMed ID: 29316525 [TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase. Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542 [TBL] [Abstract][Full Text] [Related]
18. Anti-peptide immunoglobulins from rabbit and chicken eggs recognise recombinant human dihydroorotate dehydrogenase and a 44-kDa protein from rat liver mitochondria. Knecht W; Köhler R; Minét M; Löffler M Eur J Biochem; 1996 Mar; 236(2):609-13. PubMed ID: 8612635 [TBL] [Abstract][Full Text] [Related]
19. Plant dihydroorotate dehydrogenase differs significantly in substrate specificity and inhibition from the animal enzymes. Ullrich A; Knecht W; Piskur J; Löffler M FEBS Lett; 2002 Oct; 529(2-3):346-50. PubMed ID: 12372626 [TBL] [Abstract][Full Text] [Related]